PELMEG is a medicinal product designed as a biosimilar to the original pegfilgrastim, a long-acting form of the human granulocyte colony-stimulating factor (G-CSF). It is specifically engineered to stimulate the production of white blood cells (neutrophils) in the bone marrow, helping the body to fight infections, especially in patients undergoing chemotherapy that can significantly lower blood counts. PELMEG is commonly used as a preventive treatment for neutropenia, a condition characterized by an abnormally low count of neutrophils, reducing the risk of infection in cancer patients. It is administered through subcutaneous injection and is recognized for its role in supporting the immune system during cancer treatment, thereby improving the quality of life for patients by minimizing the duration and severity of neutropenia-related complications.